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Prognostic stratification in childhood cancer is the key to appro-
priate treatment. Clinical grouping is of continued value but the
future lies in molecular characterisations that predict clinical
behaviour. Use of multimodal therapy in childhood rhabdo-
myosarcoma, incorporating multiagent chemotherapy, has led to
cure rates of over 60% (Crist et al, 1995). It has been established
that older age at presentation, higher stage of disease and certain
primary sites are adverse prognostic factors (Crist et al, 1990).
Stratification of tumours into histological subgroups has been
more controversial. For example, alveolar histology was identified
as an independent adverse prognostic factor in the IRS (Intergroup
Rhabdomyosarcoma Study) I and II studies (Crist et al, 1990),
although this was not found in the IRS III study (Crist et al, 1995)
probably because more aggressive treatment was given to alveolar
tumours. 
Identification of histological subtypes has been an evolving area
that has led to the incorporation, into the alveolar category, of
tumours with only minimal alveolar histology and/or the solid
variant form of alveolar (Tsokos et al, 1992). Moreover a molec-
ular correlate with the histological subdivision has been proposed
whereby a characteristic reciprocal chromosomal translocation,
t(2;13)(q35;q14), is considered diagnostic for alveolar histology
(Scrable et al, 1989). The molecular changes involved in the
t(2;13) translocation are well characterised and involve the disrup-
tion of the PAX3 transcription factor on chromosome 2 and its
fusion in-frame with the transactivating 3′ end of the FKHR gene
on chromosome 13 (Valentine et al, 1989; Galili et al, 1993;
Bennicelli et al, 1995). A variant translocation, t(1;13)(p36;q14),
is also found in alveolar rhabdomyosarcoma. The rearrangement is
analogous and involves disruption of PAX7 on chromosome 1 and
fusion to the FKHR transcription activation domain (Davis et al,
1994). There is emerging evidence that the 2 rearrangements are
associated with distinct clinical phenotypes; the t(2;13)(q35;q14)
cases occur in older patients and have a more aggressive behaviour
(Kelly et al, 1997). 
The cloning of the genes at the breakpoints of these transloca-
tions has allowed the development of molecular techniques to
supplement classical cytogenetics in the diagnosis and classi-
fication of small round cell tumours. Both fluorescence in situ
hybridisation (FISH) (McManus et al, 1996b) and reverse tran-
scriptase–polymerase chain reaction (RT-PCR) (Downing et al,
1995; Anderson et al, 1997) can be used on snap-frozen tumours to
indicate disruption of the genes and expression of the fusion tran-
scripts. The discovery of characteristic translocations associated
with other small round cell tumours means that these techniques
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Summary Rhabdomyosarcoma has 2 major histological subtypes, embryonal and alveolar. Alveolar histology is associated with the fusion
genes PAX3-FKHR and PAX7-FKHR. Definition of alveolar has been complicated by changes in terminology and subjectivity. It is currently
unclear whether adverse clinical behaviour is better predicted by the presence of these fusion genes or by alveolar histology. We have
determined the presence of the PAX3/7-FKHR fusion genes in 91 primary rhabdomyosarcoma tumours using a combination of classical
cytogenetics, FISH and RT-PCR, with a view to determining the clinical characteristics of tumours with and without the characteristic
translocations. There were 37 patients with t(2;13)/PAX3-FKHR, 8 with t(1;13) PAX7-FKHR and 46 with neither translocation. One or other of
the characteristic translocations was found in 31/38 (82%) of alveolar cases. Univariate survival analysis revealed the presence of the
translocation t(2;13)/PAX3-FKHR to be an adverse prognostic factor. With the difficulties in morphological diagnosis of alveolar
rhabdomyosarcoma on increasingly used small needle biopsy specimens, these data suggest that molecular analysis for PAX3-FKHR will be
a clinically useful tool in treatment stratification in the future. This hypothesis requires testing in a prospective study. Variant t(1;13)/PAX7-
FKHR appears biologically different, occurring in younger patients with more localised disease. © 2001 Cancer Research Campaign
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BJOC 01-2008 831-835  10/9/01  2:06 pm  Page 831also have a role to play in differential diagnosis and the develop-
ment of new molecular classifications. 
Previous studies (Douglass et al, 1993) to define the role of reci-
procal translocations in rhabdomyosarcoma have been limited by
difficulties in establishing karyotypes and by the limited avail-
ability of frozen tissue for FISH or RT-PCR. We have developed
an RT-PCR assay, which works on formalin-fixed tissue
(Anderson et al, 1997) and allows a more extensive study of
archival material from patients for whom there are detailed data of
treatment and outcome. We have analysed a group of 91 rhab-
domyosarcomas for the presence of the PAX3-FKHR and the
PAX7-FKHR fusions using a combination of the techniques of RT-
PCR, FISH and classical cytogenetics, and correlated these results
with tumour phenotype and clinical outcome. Because of the
changes in definition of alveolar histology over time, it was prob-
lematic to correlate histological type, molecular findings and clin-
ical outcome. Re-review of histology of the entire tumour set has
proved difficult due to sample availability. This study therefore
presents only a correlation between molecular pathology and
outcome, rather than a comparison of genotype with histology.
Molecular pathology has the advantage of being less subjective,
particularly with small samples. 
PATIENTS AND METHODS 
Patient population and eligibility 
Survival analysis was performed on 91 patients who had unequiv-
ocal evidence for the presence or absence of the characteristic
fusion genes. Patient selection was therefore determined by the
availability of material for molecular analysis and/or whether the
tumour had produced successful metaphase chromosomes. All
were treated in UK children’s cancer centres between 1982 and
1997, and had a clear histological diagnosis of rhabdomyosar-
coma. Analysed patients were aged between 4 months and 23
years with a mean of 7 and a median of 5 years. Three patients
were aged over 18 years but were treated on paediatric
chemotherapy regimens. Of analysed patients, 63 patients were
boys and 28 were girls. 45 (49%) were treated with the SIOP
(International Society of Paediatric Oncology) MMT89 (malig-
nant mesenchymal tumour) protocol and 22 (24%) with the closely
related MMT95 protocol, representing 19% of all UK patients
entered in these 2 trials. 5 patients were treated before 1989 in the
Royal Marsden Hospital using the Rapid VAC protocol (Pinkerton
et al, 1991) and 19 others (20%) were treated since 1989 in UK
paediatric cancer centres using other multimodality and multiagent
chemotherapy protocols of similar intensity to the MMT regimens.
All patients were treated with a combination of drugs including
vincristine, ifosfamide (or cyclophosphamide), and actinomycin
D. Higher stage tumours and some alveolar tumours additionally
received epirubicin, etoposide and carboplatin. All patients were
treated with intensive chemotherapy and surgery, with or without
radiotherapy for local control. High-dose therapy with bone
marrow or stem cell rescue in first remission was limited to
metastatic patients or patients with stage 3 disease and alveolar
histology. 
Survival and outcome data were obtained from the UKCCSG
data centre, Leicester, UK for the 74% of patients treated on the
SIOP MMT protocols. Records of non-MMT patients were
retrieved from participating hospitals’ own databases. 
Molecular and cytogenetic analysis 
Cytogenetic data were available from 46 rhabdomyosarcoma cases
as a separate study surveying the karyotypes of this tumour group
on behalf of the United Kingdom Cancer Cytogenetics Group
(Gordon et al, 2001) including data from 7 previously published
cases (Roberts et al, 1992; Bown et al, 1994; Yule et al, 1995;
McManus et al, 1996a; Weber-Hall et al, 1996). 35 of these cases
were included on the basis of unequivocal evidence for the pres-
ence or absence of the rearrangements associated with the known
fusion genes and breakpoints at the PAX3 or PAX7 and FKHR loci.
Cytogenetic evidence for absence of the fusion genes required
complete abnormal karyotypes with no rearrangements or double
minutes, which can be associated with fusion gene amplification
or cryptic translocations. 3 further cases with double minutes were
subsequently included because molecular analysis indicated the
presence of the PAX7-FKHR fusion. 11 cases were included on the
basis of unequivocal cytogenetic data alone. Suitable material was
available for analysis by another methodology in 16/20 cases with
and 11/18 cases without a translocation and there was complete
concordance between the cytogenetic and molecular results. 
80 tumours had material available for molecular studies, either
as freshly resected samples (for making touch imprints and then
freezing), as snap-frozen resections or biopsies, or as formalin-
fixed, paraffin-embedded tissue. The method of analysis was RT-
PCR on RNA extracted from frozen (n = 47) or fixed (n = 39)
material or interphase FISH (n = 29). In only 35 tumours did the
translocation status rely on a single molecular test (RT-PCR on
frozen (n = 16) or fixed (n = 19) tissue). 29 tumours were analysed
by 2 methods and 16 by 3 methods, again with complete concor-
dance of translocation status. 
Interphase and metaphase FISH studies for the rhabdomyosar-
coma translocations were performed using chromosome 13
cosmids flanking the FKHR gene as previously described (Biegel
et al, 1995). Cosmids were labelled with rhodamine-4-dUTP or
fluorescein-11-dUTP, respectively, so that intact chromosomes 13
in interphase and metaphase nuclei would be seen as red/green
doublets whilst disruption would result in separation of the signals.
A minimum of 50 images were captured and examined per tumour
and interpretation of results was performed with observer blinding
to clinical details of the cases. All FISH results were confirmed by
another method. The identity of the partner for FKHR in cases
with disruption was determined by RT-PCR. 
Fixed tissue which was used for RT-PCR was cut from blocks
which contained predominantly tumour. Likewise, the pathology
reports of the blocks taken adjacent to the snap-frozen samples
were reviewed to confirm that the latter were predominantly
tumour. RNA was prepared using Trizol reagent (GIBCO BRL,
Gaithersburg MD) as previously described (Anderson et al, 1997).
1 µ g of RNA was reverse transcribed using random hexamer
priming and Superscript II reverse transcriptase (GIBCO BRL)
according to the manufacturer’s instructions. The resulting cDNAs
from fixed tumour were amplified for PAX3-FKHR and PAX7-
FKHR by nested RT-PCR using previously published primers and
conditions (Anderson et al, 1997). RNA from snap-frozen tumour
was assayed by single round RT-PCR using the following novel
primer pairs and conditions: (PAX3-FKHR forward gcactgtacac-
caaagcacg, reverse ctgtggattgagcatccacc, annealing 60˚C and 1.5
mM MgCl2; PAX7-FKHR forward aaccacatgaacccggtcag, reverse
aactgtgatccagggctgtc, annealing 55˚C, and 1.5 mM MgCl2, 30
cycles). The expression of the housekeeper genes β -actin and/or
832 J Anderson et al 
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fiable RNA. Amplified RT-PCR products were separated on 2%
ethidium-stained agarose gels and the identity of the fusion gene
confirmed by automated sequencing and/or hybridisation to
internal PAX3-or PAX7-specific oligonucleotide probes. ‘No
RNA’ and ‘no cDNA’ negative controls were included in each
assay. The methodology for formalin-fixed tissue using nested
PCR has been described previously (Anderson et al, 1997).
Briefly, formalin-fixed tumour samples known to contain either
the  PAX3-FKHR,  PAX7-FKHR or no fusion gene (based on
analysis of frozen aliquots of the same tumour) were used as
controls. cDNA synthesised from test formalin-fixed tumour
samples and controls were included in each assay and used as
templates for amplification of both the FKHR fusions and 2 house-
keeper genes (actin and/or 18S RNA) in a nested PCR reaction.
The quality of RNA extracted from each fixed tumour sample was
deemed to be informative for analysis of its PAX3/7-FKHR status
by RT-PCR if the housekeeper gene product measured after 22
cycles was of equivalent or greater intensity to the controls (a
cycle number of 22 for amplification of the housekeeper genes
had been shown previously to result in the best discrimination of
RNA quality). PCR product separation and identification were
performed as for frozen samples. Quantitation of PCR products
was performed by measuring band intensity on an ethidium
bromide-stained agarose gel using NIH software. For all pre-PCR
stages, but especially those involving formalin-fixed tissue, strict
precautions were taken to prevent DNA contamination of
reactions. 
Just under 50% of fixed tumour blocks analysed by RT-PCR
(39/79) gave informative results. 20 of these had at least one other
additional technique performed, all showing concordance of
results. The clinical characteristics of the 40 cases from which
RNA could not be amplified were similar to those with good
quality RNA, hence this criterion should not have introduced any
bias. 
Statistical analysis 
Survival data were collected after the completion of the molecular
analysis. Event-free survival was defined as the time from diag-
nosis until the first occurrence of an event (relapse, death or
disease progression) or last clinical contact; and overall survival
was estimated in terms of time from diagnosis until death or the
date of last clinical contact. Overall survival and event-free
survival were estimated by the method of Kaplan and Meier. 
RESULTS 
Occurrence of the t(2; 13) & t(1; 13) translocations
according to clinical phenotype 
There were 37 tumours with t(2;13)/PAX3-FKHR, 8 with
t(1;13)/PAX7-FKHR and 46 with neither (Table 1). Overall, more
than one methodology was used in 45 cases. There was concor-
dance of results in these cases justifying the inclusion of patients
where only one methodology was used. Sequencing of PCR prod-
ucts from the t(1;13)/PAX7-FKHR and t(2;13)/PAX3-FKHR
assays showed no variability in breakpoints or sequence. 
There is a statistically significant association between
t(2;13)/PAX3-FKHR and higher-stage disease and between the
absence of a translocation and lower-stage disease (P = 0.006,
Fischer’s exact test, when grouping SIOP stages 1 & 2 and stages
3 & 4). The numbers of cases with the t(1;13)/PAX7-FKHR
translocation is too small to reach statistical significance although
an observable trend suggests that they are more akin to the cases
with neither translocation in terms of clinical stage (Table 1).
Similarly, the median ages are significantly different with the
t(2;13)/PAX3-FKHR being seen in older children than either the
t(1;13)/PAX7-FKHR or neither translocation. These median ages
are 9, 3 and 4 years respectively and the age differences are signif-
icant (P = 0.001 Kruskal–Wallis Test). There is no significant
association between translocation status and disease site. 
Rhabdomyosarcoma and characteristic translocations 833
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Table 1 Clinical features of patients with characteristic translocations and patients lacking these translocations. 
Number Histology* Gender m/f Median age Sites Favourable/unfavourable sites SIOP stage % stages 1&2 % stages 3&4 
t(1;13) 8 alv 6 5/3 3 gen 1 5/8=64% 1=3 62 38 
emb 1 h&n 3 2=2 
rms-nos 1 orb 1 3=1 
limb 3 4=2 
t(2;13) 37 alv 25 27/10 9 gen 2 8/37=22% 1=10 37 63 
emb 8 h&n 4 2=4 
rms-nos 3 orbit 2 3=8 
rms-undiff 1 hep 4 4=15 
limb 12 
perineum 2 
p/m 2 
syst 2 
trunk 7 
Neither 46 alv 7 31/15 4 gen 9 14/46=30% 1=20 72 28 
emb 34 h&n 5 2=13 
rms-nos 5 limb 10 3=5 
p/m 9 4=8 
syst 1 
thor 1 
trunk 3 
blad 5 
Favourable sites are defined as genitourinary (non bladder prostate) and head and neck (non parameningeal). Gen = genitourinary; h&n = head and neck; 
p/m = parameningeal; syst = systemic; thor = thoracic; blad = bladder; hep = hepatobiliary; orb = orbital. *Histological subtype is that of the original central
pathology review (when carried out) or the local pathologist’s report: alv = alveolar; emb = embryonal; nos = not otherwise specified; undiff = undifferentiated. 
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The median follow-up for all 91 cases is 3.4 years. In univariate
analysis of all patients, age, stage, histological risk group and pres-
ence of t(2;13)/PAX3-FKHR translocation were statistically
significant adverse prognostic factors for event-free and overall
survival (Figure 1 A, B and data not shown). We were interested in
the prognostic impact of translocations amongst patients with
localised disease where treatment intensification is an option.
Among 66 non-metastatic patients, overall and event-free survival
were significantly worse in the patients with t(2;13)/PAX3-FKHR
than in those without (Figure 1C, D). 
DISCUSSION 
This study describes the largest analysis to date of the clinical
impact of characteristic chromosomal translocations in childhood
rhabdomyosarcoma. Survival analysis indicates that the presence
of a t(2;13)/PAX3-FKHR is an adverse prognostic factor. The
majority (74%) of patients were treated using the same SIOP
MMT protocols, and non-MMT patients were treated in a broadly
similar manner. More aggressive first-line therapy was given to
some of the more recently diagnosed patients with alveolar
histology, most of whom had t(2;13)/PAX3-FKHR. If anything,
this may have led to an underestimate of the prognostic impact 
of the t(2;13)/PAX3-FKHR translocation. The comparative prog-
nostic value of this tumour-specific translocation compared with
alveolar histology needs to be assessed in a prospective study with
uniform pathological diagnostic criteria and central review. 
The number of cases with the variant translocation
t(1;13)/PAX7-FKHR was too small to allow statistically signifi-
cant analyses. However, the picture which is emerging from this
and other studies (Kelly et al, 1997) is that these tumours have
classical alveolar histology but a different clinical phenotype
including a younger age at presentation, lower disease staging and
better prognosis. Thus they appear biologically distinct from the
t(2;13)/PAX3-FKHR tumours despite indistinguishable histo-
logical features. 
There is a disproportionately high incidence of alveolar
histology in the study for 2 reasons. First, because of the inclusion
of tumours with karyotype information and therefore the auto-
matic exclusion of cases in which cytogenetic analysis was unsuc-
cessful, not attempted or equivocal. Second, because of the high
incidence of extremity primaries, which are more likely to be of
the alveolar subtype and which are more likely to have either
primary surgery or a large biopsy, providing sufficient material for
molecular analysis. This selection is likely to occur to a similar
extent in prospective studies, largely because of the trend towards
minimally invasive diagnostic procedures and the deferment of
definitive surgery. 
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Figure 1A Overall survival by translocation status. Significantly poorer
survival (P < 0.0001) for t(2;13) as compared to neither translocation
0123 4 5 6 7 89 1 0 11 12
Time in years
0
25
50
75
100
%
 
S
u
r
v
i
v
i
n
g
B
t(1;13)
neither translocation
t(2;13)
0123456789 1 0 1 1 12
Time in years
0
25
50
75
100
%
 
S
u
r
v
i
v
i
n
g
neither translocation
t(2;13)
t(1;13)
D
0 1 2 3 4 5 6 7 8 9 10 11 12
Time in years
0
25
50
75
100
%
 
S
u
r
v
i
v
i
n
g
neither translocation
t(1;13)
t(2;13)
C
Figure 1B Event-free survival by translocation status. Significantly poorer
survival (P < 0.0001) for t(2;13) as compared to neither translocation
Figure 1C 66 stage 1–3 patients. Overall survival by translocation status.
Significantly poorer survival (P < 0.0001) for t(2;13) as compared to neither
translocation
Figure 1D 66 stage 1–3 patients. Event-free survival by translocation
status. Significantly poorer survival (P = 0.005) for t(2;13) as compared to
neither translocation
BJOC 01-2008 831-835  10/9/01  2:06 pm  Page 834With the increasing use of minimal biopsies and a move away
from up-front surgery, it seems likely that small areas of alveolar
architecture in an otherwise typical embryonal or undifferentiated
tumour might be missed despite rigorous histological examination
of the biopsy specimens. The identification of the presence of the
t(2;13) translocation/PAX3-FKHR fusion as an adverse prognostic
factor may have an impact on treatment in such cases. Prospective
studies are needed, incorporating rigorous application of uniform
diagnostic histological criteria and molecular analyses, to confirm
our findings and clarify the relative prognostic significance of
t(1;13)/PAX7-FKHR, t(2;13)/PAX3-FKHR and alveolar histology.
Ultimately an understanding of how the fusion proteins contribute
to tumorigenesis and the aggessive behaviour of the alveolar
subtype may suggest novel treatment approaches. 
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